Shandong Sito subsidiary receives European CEP for dexamethasone

Shandong Sito Biotechnology (SZSE:300583) announced today that its subsidiary, Shandong Sirui Pharmaceutical, has received the Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its dexamethasone raw material. This certification allows Sirui Pharmaceutical to market the dexamethasone raw material in international markets that recognize the CEP, potentially expanding its market reach and strengthening its competitive position in the chemical raw material sector. The CEP, valid for five years from June 17, 2025, confirms the quality and suitability of Sirui Pharmaceutical's dexamethasone for pharmaceutical use. Dexamethasone, a synthetic glucocorticoid, is used to treat a variety of conditions including rheumatoid arthritis and allergic reactions. According to Yao Rong Cloud data, five other global dexamethasone raw material producers hold valid CEP certifications. Global demand for dexamethasone raw materials in 2022 was 15 tonnes. The company cautions that actual sales depend on various internal and external factors, including policy changes and market development, and that there remains uncertainties, advising investors to exercise caution.